about
Theophylline-gentisic acid (1/1).Laser desorption single-conformation UV and IR spectroscopy of the sulfonamide drug sulfanilamide, the sulfanilamide-water complex, and the sulfanilamide dimer.Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation.2-(4-Amino-benzene-sulfonamido)-4,6-dimethyl-pyrimidin-1-ium 2-carb-oxy-4,6-dinitro-phenolate.4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzene-sulfonamide-4-nitro-benzoic acid (1/1).tert-But-yl(2-hy-droxy-eth-yl)aza-nium 4-[(1,3-thia-zol-2-yl-aza-nid-yl)sulfon-yl]anilineN-(4,6-Dimethyl-pyrimidin-2-yl)-4-(oxolan-2-ylamino)benzene-sulfonamide4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)benzene-sulfonamide-2-nitro-benzoic acid (1/1).Polymorphs, hydrates and solvates of a co-crystal of caffeine with anthranilic acid.Creation of a ternary complex between a crown ether, 4-aminobenzoic acid and 3,5-dinitrobenzoic acid.On the hydrates of codeine phosphate: the remarkable influence of hydrogen bonding on the crystal size.Shape and size mimicry in the design of ternary molecular solids: towards a robust strategy for crystal engineering.Cocrystal habit engineering to improve drug dissolution and alter derived powder properties.Multicomponent ternary cocrystals of the sulfonamide group with pyridine-amides and lactams.The Cold Contact Method as a Simple Drug Interaction Detection System
P2860
Q34266265-8309AAAA-171C-4717-9C31-9246C9ED778BQ36379040-6FDF1F53-2ADA-4DA3-84D3-A65744CC0C9AQ39234260-C471C45E-DC50-4252-8247-95950D02C2BFQ39924901-4EC8C97D-6D0B-464E-97FE-72CB8AF2D9ECQ42023175-3CE726BE-7AD5-45EF-9968-9488C530A000Q42323532-0FF91751-6F14-48FD-AC1F-D6797C11FFCAQ42385054-4C332B43-8870-449B-BCC6-8B91C0412D04Q43241803-610D5AE6-7CE9-4F25-B4B5-F52EDC394CEEQ44983103-23F2694C-7029-4174-A183-B572E4C32815Q46944452-428A2770-BA5B-407F-9046-0FAEF38FADA3Q47178195-B39B8C11-1A99-4D37-98AD-ECF4A78D48E4Q47350010-F5ED2ABE-250D-4770-8474-7C38914434C1Q51706707-A45A5A75-00BE-44D8-83F5-0E6936736B57Q51724730-D5A5D0DA-8045-4C9D-A40A-9C50C58DE982Q58644597-CE508E01-A77F-41D7-A136-30863D941AB2
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Sulfa drugs as model cocrystal formers.
@ast
Sulfa drugs as model cocrystal formers.
@en
type
label
Sulfa drugs as model cocrystal formers.
@ast
Sulfa drugs as model cocrystal formers.
@en
prefLabel
Sulfa drugs as model cocrystal formers.
@ast
Sulfa drugs as model cocrystal formers.
@en
P356
P1476
Sulfa drugs as model cocrystal formers.
@en
P2093
Mino R Caira
P304
P356
10.1021/MP070003J
P407
P577
2007-05-04T00:00:00Z